CSTONE PHARMACEUTICALS

http://www.cstonepharma.com/

Weekly News Amount
Total
${lastRankDetail.pages.length}
Financing ${lastRankDetail.financing_pages.length}
Product ${lastRankDetail.product_pages.length}
Negative ${lastRankDetail.sentiment_pages.length}
CSTONE PHARMACEUTICALS is a biopharmaceutical company dedicated to the development of a new generation of therapeutic drugs. It mainly has a product line in five treatment areas, including cancer, cardiovascular disease, rheumatoid arthritis, blood diseases and autoimmune diseases, with the aim of helping patients solve their clinical needs

Transactions

Funding 2 Fundings
Date Amount Round Relative News
Jul 2016 150 million USD Series A
May 2018 260 million USD Series B Tumor immune drug research and development company CSTONE PHARMACEUTICALS completed round B financing of 260 million US dollars

Signals

Events ${currentEventsPage.count} Events
Events (${currentEventsPage.count}) Date
Nothing Happens :-(
${e.desp} ${e.date}
News ${ rankDetail.pages.length } News Articles ${currentTimeRange.start} ~ ${currentTimeRange.end}
Article (${rankDetail.pages.length}) Tag
${article.en_title} ${article.tag}
Industry Financing Info

Research

Intelligence 0 Research Briefs

Competition

Competitors 5 Competitors
Company Industry Series Amount Announced Date

ANTENGENE

ANTENGENE is an innovative biopharmaceutical company focusing on the development of clinical new drugs, based in China and the Asia - Pacific region, bringing the most cutting-edge innovative therapies to patients through the development of clinical research products from early to late and the introduction of mature products already on the market in the world. Its team has rich experience in clinical research and development, new drug supervision and marketing in the Asia - Pacific region, and will cooperate with academic research institutions and leading biopharmaceutical enterprises around the world in disease areas with high morbidity and urgent research needs in Asia - Pacific countries and regions

Healthcare

series C

97 million USD

20/7/2020

DingKeYiLiao

DingKeYiLiao is a high-tech company specializing in the research and development and production of vascular interventional medical treatment products, and has completed several registration tests and animal experiments of three types of products, among which DingKeYiLiao has the pre-market clinical trial of coronary drug balloon DCB ( Drug Coated Balloon ) Dissove TM with independent PCT intellectual property rights

Healthcare

series B

Nearly 100 million CNY

18/8/2020

Akesobio

Akesobio is an innovative biopharmaceutical company headquartered in the National Health Industry Base of Torch Development Zone, Zhongshan City, Guangdong Province. The Haigui Entrepreneurship Team led by experts from the National " Thousand People Plan" was established in March 2012. We are committed to the discovery and development of innovative antibody drugs with independent intellectual property rights to meet the needs of the pharmaceutical market at home and abroad. At present, the company has built a platform for the whole process of research and development and industrialization of biopharmaceutical with international level

Healthcare

series C

Hundreds of millions CNY

1/11/2018

Adagene

Adagene is committed to developing a new generation of biopharmaceutical companies with therapeutic and diagnostic antibody technology, using its own dynamic precision antibody technology ( DPL ) to develop new drugs leading the industry

Healthcare

series C

50 million USD

27/3/2018

EUCURE BIOPARMA

EUCURE BIOPARMA is an innovative antibody drug developer with a monoclonal antibody preparation platform, in vivo efficacy detection platform, in vitro antibody analysis platform and so on. It mainly provides products such as tumor immune antibody drugs, tumor immune checkpoint antibodies and so on for users, involving targeting tumor, immune anti - cancer, cardiovascular and other diseases

Healthcare

series B

120 million CNY

27/3/2018